Seattle, United States
Sana Biotechnology, Inc., founded in 2018, stands at the forefront of the Biotechnology sector with a mission to create and deliver engineered cells as medicines. With headquarters in the United States, Sana has rapidly expanded, amassing over 350 employees across Seattle, Cambridge, and South San Francisco.
Sana is committed to addressing challenging medical conditions through its novel approach to cell and gene therapy. The company focuses on three primary pillars: gene repair and control, ex vivo differentiation of pluripotent stem cells, and scalable manufacturing solutions to improve accessibility and affordability. These ambitions position Sana as a leader in pursuing next-generation therapies for untreatable diseases.
In April 2026, Sana secured a substantial $25.00M post-IPO equity investment from the prestigious Mayo Clinic. This investment highlights confidence in Sana's innovative potential and scalability, making it an attractive prospect for investors in the healthcare and life sciences industries.
